7, 2025 Journal of Obesity, A Comprehensive Review on Weight Gain following Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists for Obesity, May 10, 2024 KFF, Poll: 1 in 8 Adults Say They Are Currently Taking a GLP-1 Drug for Weight Loss, Diabetes or Another Condition, Even as Half Say the Drugs Are Difficult to Afford, Nov
These findings may impact ongoing legal reviews concerning the drugs safety
This may be relevant for people with malabsorption disorders such as Crohn's disease or coeliac disease, though it's important to note that for pernicious anaemia, intramuscular hydroxocobalamin injections remain the first-line treatment in the UK, as recommended by NICE and the British Society for Haematology
DAC vs no-DAC difference: DAC users notice a more gradual onset because GH elevation is sustained but moderate
For beginners, the focus should be on conservative protocols that prioritize safety and gradual progression